Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
NCT06754098Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in thymidine kinase 2 deficiency (TK2D). Primary endpoints: Medical Research Council Scale for Muscle Strength at Month 24, 6-minute walk test at Month 24 and 8 more. Started Jan 2025; status: recruiting.
02
Conditions
thymidine kinase 2 deficiency (TK2D)
Beyond the preview
Go deeper on NCT06754098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754098.